Does in range (>12%) device oversizing improve clinical outcomes compared to below range (0%-12%) device oversizing in patients with large annuli valves undergoing TAVR with 34mm Evolut R/PRO+ valves?
In patients with large annuli undergoing TAVR with 34mm Evolut valves, >12% device oversizing is associated with better clinical outcomes compared to 0-12% oversizing.
Results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry in patients with large annuli valves using 34mm Evolut R/PRO+ valves suggest that in range (>12%) device oversizing delivered better clinical outcomes than implantation with below range (0%-12%) device oversizing.
Dallan et al. (Wed,) studied this question.